A b s t r a c t
PAX genes are a family of transcription factors with wider fundamental roles during organogenesis. Comparison of the expression patterns of fish, amphibian, and mammalian PAX-2/5/8 genes revealed that the tissue specificity of PAX-2/5/8 gene family expression overall is evolutionarily conserved. 1 During embryogenesis, the PAX5/B-cell-specific activator protein (BSAP) gene is expressed transiently in the mesencephalon and spinal cord with a spatial and temporal expression pattern that is distinct from that of other PAX genes in the developing central nervous system. Later, the expression of the BSAP gene shifts to the fetal liver, where it correlates with the onset of B lymphopoiesis. 2 Pax-5 is a pan-B cell transcription factor essential for B-cell commitment by inducing expression of multiple B-cell genes while at the same time repressing alternative pathways of hematopoietic differentiation by inhibiting the expression of cytokine receptors such as M-CSF and Notch-1. [3] [4] [5] In hematopoietic cells, Pax-5 expression is limited to B cells and its expression designates true B-cell differentiation. 6, 7 Therefore, Pax-5 expression can be used for diagnostic purposes as a pan-B cell marker. 8 It also was demonstrated recently in a subset of myeloid leukemia, ie, acute myeloid leukemia with characteristic translocation t(8:21). 9 Although Tiacci et al 9 also found that Pax-5 is an excellent marker of B-cell differentiation of acute lymphoblastic leukemia, Zhang et al 10 found its expression in 3 of 6 T-cell acute lymphoblastic leukemias, but it is not clear which criteria were used for the establishment of T-cell lineage. The expression of the PAX5 gene also was described as a frequent event in poorly differentiated neuroendocrine carcinomas and superficial transitional cell carcinoma of the bladder. 11, 12 The present study evaluated expression of PAX5 in nonhematolymphoid tissues with emphasis on neuroendocrine tumors and evaluated its expression in normal adult brain tissue samples.
Materials and Methods

Tissue Samples
We selected 123 formalin-fixed, paraffin-embedded tissue samples from the archives of the Department of Pathology, National Hospital-Norwegian Radium Hospital, Oslo, Norway, and from the Department of Pathology, Royal University Hospital, Saskatoon, Canada, in an anonymous manner in agreement with the regulations of the Regional Ethics Committee.
We evaluated 51 neuroendocrine tumors by immunohistochemical analysis for Pax-5 expression. Samples were as follows: small cell carcinoma: lung, 17; cervix or corpus uteri, 7; gastrointestinal tract, 2; and other sites, 3; carcinoid tumors: appendix, 6; small bowel, 3; and other sites, 9; atypical carcinoid tumor, cervix, 2; and neuroendocrine tumors, pancreas, 2. We also studied 15 mesonephric tissue samples, 21 cervical carcinomas, and 12 various other tissue samples. All cervical carcinomas were primary tumors. Cervical squamous lesions were not included.
Representative tissue sections with no pathologic findings of adult brain tissues were obtained as a part of postmortem evaluation of 24 samples from 4 patients with no neurologic disease. Two were male (64 and 24 years old), and 2 were female (67 and 16 years old).
Immunohistochemical Analysis
The paraffin blocks were cut at 4 to 6 µm, dried overnight at 60°C, and deparaffinized in xylene. Subsequently, sections were rehydrated through graded alcohols into water. Heatinduced epitope retrieval was achieved by boiling sections in EDTA buffer, pH 8.9, in an Electrolux microwave oven (Stockholm, Sweden) at 1,000 W for 20 minutes (4 times for 5 minutes). Thereafter, sections were allowed to cool at room temperature for 20 minutes, rinsed thoroughly with water, and placed in Tris-buffered saline (TBS) for 5 minutes. Endogenous peroxidase was blocked with Peroxidase Block solution (provided in the EnVision+ kit; DakoCytomation, Glostrup, Denmark) for 5 minutes, and slides were rinsed and washed with TBS. The sections were incubated with primary monoclonal mouse anti-BSAP/anti-Pax-5 (clone 24, dilution 1:40; Transduction Laboratories, Lexington, KY) for 30 minutes at room temperature. The immunostaining was performed using the EnVision+ method according to the manufacturer's instructions. Appropriate positive and negative control samples were used.
Scoring of the immunostaining intensity in the nuclei was done as follows: 0, no staining; 1+, weak staining; 2+, moderate staining; and 3+, strong staining. For evaluating the differences in immunostaining in neuroendocrine tumors, the staining was quantitated by recording the exact percentage of positive nuclei in 500 tumor cells.
Cell Culture
The Daudi 13 and NCL-H128 14 cell lines were obtained from the American Type Tissue Collection (Rockville, MD). The cells were grown in RPMI 1640 medium (Gibco/BRL, Gaithersburg, MD) supplemented with 10% fetal bovine serum supplemented with L-glutamine and penicillin/streptomycin in 25-cm 2 cell culture flasks (Nunc, Roskilde, Denmark) and incubated in a humidified carbon dioxide incubator at 37°C. The cells were harvested when they reached 90% confluence.
Immunoblotting
Cells were lysed in ice-cold NP-40 lysis buffer (1% NP-40; 10% glycerol; 20 mmol/L of Tris hydrochloride, pH 7; 137 mmol/L of sodium chloride; 100 mmol/L of sodium vanadate; 1 mmol/L of phenylmethyl sulfonyl fluoride; 0.02 mg/mL each of aprotinin, leupeptin, and pepstatin; and 10 µL/mL of phosphatase inhibitor cocktail I). All protease inhibitors were from Sigma-Aldrich, St Louis, MO. Lysates were sonicated and clarified by centrifugation. Protein quantitation was done by Bradford analysis, and 25 µg of protein per lane was resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. Proteins were transferred to PVDF immobilon membranes (Millipore, Bedford, MA). The membranes were blocked in 5% nonfat dried milk, freshly made in 20 mmol/L of Tris hydrochloride, pH 7.6; 0.136 mol/L of sodium chloride; plus 0.05% of polysorbate (Tween) (TBS-T), for 1 hour at room temperature and incubated with Pax-5 monoclonal antibody (Transduction Laboratories), diluted 1:250, overnight at 4°C. Thereafter, the blots were washed 3 times for 10 minutes in TBS-T and then incubated for 45 minutes at room temperature with horseradish peroxidase-conjugated secondary antibodies (1:5,000) diluted in 5% nonfat dried milk in TBS-T. Immunoreactivity was detected using the ECL Plus Western blotting system (Amersham Bioscience, Buckinghamshire, England). To ensure even loading, the filters were stained with naphthol blue-black (Sigma-Aldrich) and hybridized with α-tubulin (Calbiochem-Novabiochem, San Diego, CA).
Statistical Analysis
Statistical analyses were performed using the SPSS 9.0 software program, SPSS, Chicago, IL. The associations between variables were analyzed by using the χ 2 test and Fisher exact test as appropriate. Spearman correlation was used to determine the correlation of the percentage of positive cells and the neuroendocrine cell tumor category.
Results
Results of immunostaining with anti-Pax-5 antibody are illustrated in ❚Image 1❚ and summarized in ❚Table 1❚ and ❚Table 2❚. The Daudi cell line showed strong nuclear expression of Pax-5 (Image 1A), comparable to Pax-5 expression in the pre-B acute lymphoblastic leukemia in the sections of the bone marrow (Image 1B). The small cell carcinoma cell line, NCL-H128, demonstrated weaker and more variable expression of Pax-5 (Image 1C), which also was comparable to Pax-5 expression in the small cell carcinoma metastatic to the bone marrow (Image 1D).
Of the undifferentiated neuroendocrine tumors, 93% showed expression of Pax-5 in more than 10% of the cells. Merkel cell tumors also were positive. None of the typical carcinoid tumors expressed Pax-5 (Image 1E and Table 1 ). Two atypical carcinoids of the cervix and 2 neuroendocrine tumors of the pancreas showed variable but generally weak and/or focal expression of Pax-5. In 1 case, Pax-5 was found in fewer than 10% of the cells and could be considered as negative (Image 1F), whereas 2 of the atypical carcinoid tumors showed weak positivity (Images 1G and 1H). The difference between small cell carcinoma of various sites and other neuroendocrine tumors was significant (P = .002; r = 0.416, Spearman correlation). Mesonephric rest and hyperplasia (Image 1I and Table  2 ) showed strong nuclear staining in all cases. Squamous epithelium was negative, whereas endocervical glands showed rare cells with weak focal expression of Pax-5. This expression was distinctly weaker than the expression of Pax-5 in mesonephric tissues. Rete testis and ovarii were mainly negative, whereas epididymis showed uniformly strong expression. Mesonephric carcinomas showed distinct nuclear staining in the majority of cases (Image 1J). Of the cervical carcinomas, clear cell carcinoma, undifferentiated carcinoma, and endometrial and endocervical carcinomas were negative with only focal expression in a small number of cells in 1 case of endocervical carcinoma. However, serous adenocarcinoma and adenosquamous carcinoma had focal staining. Sections of the normal adult brain tissues showed focal expression of Pax-5 in the following areas: neurons of the area postrema of the medulla oblongata (Image 1K), periaqueductal gray matter in the midbrain (Image 1L), and occasional scattered cells of the caudal nucleus nervi trigemini. All other mature brain tissues were completely negative for Pax-5.
Nuclear Pax-5 expression also was found in the smooth muscle of the uterus and in rare nuclei of the small glandular structures in the prostate consistent with nephrogenic adenoma, whereas no expression was found in lung tissues, kidneys, skin, or tissues of the gastrointestinal tract or thyroid. In many organs, small lymphocytes consistent with small B cells showed strong expression of Pax-5.
Western blot analysis using the same monoclonal antibody used for immunohistochemical analysis confirmed the expression of Pax-5 in the pre-B lymphoblastic cell line, Daudi, and the small cell carcinoma cell line, NCL-H128 
Discussion
The expression of Pax-5 in neuroendocrine tumors was reported by Dong and coauthors. 11 Although these authors, in addition to immunohistochemical detection, also demonstrated expression of Pax-5 messenger RNA, we used Western blot to show that the Pax-5 protein product as detected by monoclonal mouse antibody is of identical molecular weight in lymphoblastic and small cell carcinoma cell lines. Although expression of Pax-5 was described in developing brain tissue, to the best of our knowledge, adult brain tissues were believed to show no Pax-5 expression. [15] [16] [17] However, our results indicate that Pax-5 is expressed focally even in normal adult brain tissue.
In a previous study 11 and in the present study, most remarkably, the expression of Pax-5 in neuroendocrine tumors seems to parallel the level of tumor aggressiveness. This finding is in accordance with findings of Baumann Kubetzko et al, 18 who reported that PAX5 is expressed in aggressive N-type neuroblastoma cell lines, whereas no expression was detected in S-type cells. These authors also reported that overexpression of PAX5 in the S-type cell line CA-2E restored several malignant properties, in particular anchorage-independent growth. In addition, down-regulation of PAX5 in several N-type cell lines significantly reduced their proliferation rate. It is speculated that reexpressed PAX genes promote tumor development and progression by increasing proliferation and motility while inhibiting apoptosis. 19 PAX transcription factors have been shown to have an important role in tumorigenesis (reviewed by Schafer 19 ). It was suggested that Pax-5 may aid in promoting the progression of astrocytomal malignancy. 20 Stuart et al 21 suggested a direct role for Pax-5 in the control of p53 transcription. Pax-5 and its paralogues, Pax-2 and Pax-8, were capable of inhibiting the p53 promoter and transactivation of a p53-responsive reporter in cell culture. However, this was challenged by Nutt and coauthors, 22 who showed that p53 expression is totally unaffected by the loss of Pax-5 function. Although its putative role in repression of p53 promoter is not clear, it is interesting that a number of PAX genes are located at recurring, tumor-specific chromosomal translocations, suggesting that PAX genes may have oncogenic capacity when expressed inappropriately. Second, several PAX genes are reexpressed in malignant neoplasms, usually in tumors derived from tissue in which the respective PAX gene is expressed during development. Examples include deregulated expression of PAX5 in glioblastoma multiforme, medulloblastoma, and lymphomas 20, 23, 24 and PAX3 in melanoma. 25 It is interesting that Pax-5 expression also is found in mesonephric benign and malignant tissues. As a marker of mesonephric differentiation, it seems to be possibly better than CD10 (results not shown) because in our experience, CD10 is patchy and sometimes only luminal and disturbed by stromal staining, whereas staining with Pax-5 appears strong and uniform and there is no background stromal staining. Positivity for Pax-5 in 2 of 3 serous tumors may cause diagnostic problems. In our limited experience, WT-1, known to be a useful marker of serous carcinoma, 26 is not expressed in mesonephric hyperplasia or mesonephric carcinoma (data not shown). Further studies of a wide array of carcinomas are necessary to delineate the diagnostic usefulness and clinical significance of Pax-5 expression in carcinomas.
In contrast with previously reported Pax-5 expression in the adult testis, 27 we show that no such expression can be found by immunohistochemical analysis. However, the presence of Pax-5 in some tissues of the male and female genital tract may suggest that Pax-5, in addition to Pax-2, may have a role in multiple steps of urogenital development, which may be similar to the Pax-2 and Pax-5 cooperation in midbrain and cerebellum development. 28, 29 Each cell fate is specified by a unique combinatorial code of transcription factors that function in a hierarchical and combinatorial manner. 3 The interpretation of the significance of transcription factor expression, including Pax-5, for diagnostic purposes should always take into account that transcription factors exhibit their effects in regulation of gene expression and cellular differentiation in lineage-and stage-appropriate environments. Therefore, it is not surprising that Pax-5 has an entirely different role in the hematolymphoid tissue than in neural and, possibly, urogenital development. Lagergren et al 30 nevertheless, fail to express detectable levels of their known target genes MB-1 and CD19, showing that transcription factors are able to selectively activate target genes in different tissues. In hematolymphoid tissues, however, Pax-5 seems to exert its effects on usual B-cell target genes, and it also seems to be the case when Pax-5 is found inappropriately expressed in acute myeloid leukemia. 9 The expression of Pax-5 in this setting probably explains the expression of the B-cell proteins CD79a and/or CD19 (major transcriptional targets of Pax-5 in B cells), and, indeed, it may be considered as evidence of a partial B-cell differentiation in some cases of this subtype of myeloid leukemia. From a practical standpoint, our work stresses the importance of knowledge of the spectrum of reactivity of Pax-5 when a diagnostic pathologist is faced with a Pax-5+ tumor. Obviously, one cannot interpret a positive Pax-5 immunostain as an accurate reflection of a B-cell tumor unless the lymphohematopoietic nature of the tumor has been established confidently by other means. Failure to do so could result in a misdiagnosis of a high-grade neuroendocrine carcinoma as a lymphohematopoietic lesion, a mistake that could have significant impact on patient care.
